Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Short Interest Update

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) saw a large growth in short interest during the month of November. As of November 30th, there was short interest totalling 20,600 shares, a growth of 174.7% from the November 15th total of 7,500 shares. Based on an average daily volume of 44,000 shares, the short-interest ratio is currently 0.5 days.

Global X Genomics & Biotechnology ETF Trading Down 1.6 %

GNOM stock traded down $0.17 during trading on Friday, reaching $10.27. 164,994 shares of the stock were exchanged, compared to its average volume of 57,763. The stock has a 50 day simple moving average of $10.61 and a 200-day simple moving average of $10.84. The company has a market capitalization of $75.07 million, a P/E ratio of -4.46 and a beta of 1.03. Global X Genomics & Biotechnology ETF has a twelve month low of $9.52 and a twelve month high of $12.53.

Institutional Trading of Global X Genomics & Biotechnology ETF

A number of institutional investors and hedge funds have recently modified their holdings of the company. Atria Investments Inc bought a new stake in Global X Genomics & Biotechnology ETF in the third quarter valued at about $122,000. Centaurus Financial Inc. bought a new stake in shares of Global X Genomics & Biotechnology ETF in the 2nd quarter valued at approximately $146,000. Rockefeller Capital Management L.P. acquired a new position in shares of Global X Genomics & Biotechnology ETF in the 3rd quarter worth approximately $205,000. James J. Burns & Company LLC raised its holdings in shares of Global X Genomics & Biotechnology ETF by 6.0% in the 3rd quarter. James J. Burns & Company LLC now owns 18,293 shares of the company’s stock worth $207,000 after buying an additional 1,038 shares in the last quarter. Finally, Archford Capital Strategies LLC lifted its position in shares of Global X Genomics & Biotechnology ETF by 59.1% during the 2nd quarter. Archford Capital Strategies LLC now owns 36,871 shares of the company’s stock worth $385,000 after buying an additional 13,703 shares during the period. 56.95% of the stock is currently owned by institutional investors.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.